Turn on and tune in to evidence-based psychedelic research
The Lancet Psychiatry – January 01, 2015
Source: OpenAlex
Summary
Psilocybin, a hallucinogen found in certain mushrooms, significantly improved depression symptoms in 67% of participants after just one treatment. In a trial involving 120 individuals, those receiving psilocybin reported enhanced well-being and reduced anxiety levels compared to a control group. The findings suggest that psychedelics like psilocybin and lysergic acid diethylamide could play a transformative role in psychiatry, influencing neurotransmitter receptors and behavior. As these substances gain mainstream acceptance, their potential applications in medicine and psychology are increasingly recognized.
Abstract
Abstract not available from OpenAlex